EU and US could reach trade deal this weekend - Reuters
HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO and BIO.B), a life sciences company with a market capitalization of $6.8 billion and strong financial health according to InvestingPro data, announced Monday the launch of four new Droplet Digital PCR (ddPCR) platforms, expanding its product offerings in genomics research and clinical diagnostics.
The new instruments include the QX Continuum ddPCR system and three QX700 series platforms, which were acquired through Bio-Rad’s recent purchase of digital PCR developer Stilla Technologies. With a robust current ratio of 5.99, Bio-Rad maintains strong liquidity to support its expansion initiatives.
The QX Continuum system, designed for translational research, features a qPCR-like workflow with four-color multiplexing capabilities and the ability to run up to eight discrete thermal profiles per plate.
The QX700 series platforms, aimed at academic research, environmental testing, and biopharma applications, offer seven-color multiplexing and can process over 700 samples daily with continuous loading capability.
"The newly introduced platforms complement Bio-Rad’s existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities," said Jim Barry, EVP and President of Bio-Rad’s Life Science Group, according to the company’s press release.
These additions join Bio-Rad’s existing QX200 and QX600 ddPCR systems, creating what the company describes as the most comprehensive line of digital PCR products for research and diagnostic applications. The portfolio includes over 400,000 assays.
Bio-Rad Laboratories, headquartered in Hercules, California, reported $2.6 billion in revenues in 2024 and employs approximately 7,700 people globally. The company develops products for life science research and clinical diagnostics markets. Currently trading below its Fair Value according to InvestingPro analysis, Bio-Rad is scheduled to report its next earnings on July 24, 2025. Discover more insights and 8 additional ProTips with an InvestingPro subscription.
In other recent news, Bio-Rad Laboratories reported its financial results for the first quarter of 2025, exceeding analysts’ expectations. The company achieved an earnings per share (EPS) of $2.54, significantly surpassing the forecasted $1.80. Revenue reached $585.4 million, slightly above the anticipated $573.22 million, although it marked a 4.2% decline year-over-year. Despite these challenges, Bio-Rad improved its non-GAAP operating margin to 10.8%, up from 9.7% in the same quarter last year. The company continues to invest in innovative product development, although it faces concerns over potential reductions in academic research funding. In addition, Bio-Rad is on track to close its acquisition of Stila Technology by the end of the third quarter, which is expected to expand its digital PCR offerings. Cantor Fitzgerald’s recent report highlighted Bio-Rad’s stance against the Most Favored Nation model for drug pricing, emphasizing potential shifts in the biotechnology sector. Bio-Rad’s CEO expressed concerns about the impact of drug pricing changes and proposed several solutions, including reforming Pharmacy Benefit Managers to reduce U.S. list prices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.